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Introduction: The important functions of the meniscus are shock absorption, passive stabilization and load
transmission of the knee. Because of the avascularity of two-thirds of the meniscal center region, the treatment of
tears in this area is hard. Recently, microRNAs have been proven to play an important role in the pathogenesis of
diseases. We focused on microRNA (miR)-210, which plays a wide spectrum of roles comprising mitochondrial
metabolism, angiogenesis, DNA repair and cell survival. This study aimed to investigate the effect of intra-articular
injection of synthetic miR-210 on the injured meniscus in the avascular zone.
Methods: The middle segments of the medial meniscus of Spraque Dawley rats were incised longitudinally with a
scalpel. An intra-articular injection of double-stranded (ds) miR-210 (for control group using control dsRNA) with
atelocollagen was administered immediately after injury. Four weeks and 12 weeks after the injection, we conducted a
histologic evaluation, immunohistochemical evaluation and Real-time PCR analysis. In vitro, the inner meniscus and
synovial cells were isolated from rat knee joint, and were transfected with ds miR-210 or control dsRNA. Real-time PCR
and immunohistochemical evaluations were performed.
Results: Twenty-four hours after the injection, FAM (Fluorescein amidite) labeled miR-210 was observed in the cells
around the injured site. Four weeks after the injection, the injured site of the miR-210 group was filled with repaired
tissue while that of the control was not repaired. In gene expression analysis of the meniscus, the expression of miR-210,
Collagen type 2 alpha 1 (Col2a1), Vascular endothelial growth factor (VEGF), and Fibroblast growth factor-2 (FGF2) in the
miR-210 group was significantly higher than that in the control. At 12 weeks, the intra-articular injection of miR-210 had
healed the injured site of the meniscus and had prevented articular cartilage degeneration. In vitro, miR-210 upregulated
Col2a1 expression in the meniscus cells and VEGF and FGF2 expression in the synovial cells.
Conclusions: An intra-articular injection of ds miR-210 was effective in the healing of the damaged white zone
meniscus through promotion of the collagen type 2 production from meniscus cells and through upregulated of VEGF
and FGF2 from synovial cells.Introduction
The meniscus is an important tissue for the functioning
of the knee joint, and plays a crucial role in the knee
load motion, stability and shock absorption of the knee.
The medial and lateral menisci are C-shaped fibrocarti-
laginous wedges located between the femoral condyles
and the tibial plateau [1,2]. In the human meniscus, the* Correspondence: y.kawanishi.57@gmail.com
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stated.outer 10 to 20% of the meniscus is supplied by a perime-
niscal capillary plexus, but 70 to 80% of the inner menis-
cus forms the avascular region [3,4]. Damaged meniscus
produces pain, articular cartilage injury and functional
loss of the knee joint, which is recognized as one of the
key factors of osteoarthritis (OA) of the knee, and ex-
plains the real need for effective treatment [5]. Several
studies have shown that tears in the avascular area do
not heal successfully by suture repair alone [6,7]. Failure
rates after attempted surgical repair remain high, ran-
ging from 24 to 50% for isolated meniscal tears [8]. Thisral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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of the menisci are avascular, and avascularity is consid-
ered one of the most important factors contributing to
the poor healing potential of this region [3,9]. Such un-
satisfactory outcomes have stimulated the development
of a variety of techniques designed to augment repairs
with an additional biological stimulus through synovial
rasping, trephination or application of fibrin clot or
platelet-rich plasma [10-13]. Newer techniques with in-
creasing cost and complexity are also being tested in
animal models, including local application of exogenous
growth factors or stem cells [14]. Recent literature has
suggested that synovial tissue-derived mesenchymal
stem cells may have the potential to aid in healing and
regeneration of cartilage injuries, such as those involving
the meniscus [15,16]. More effective novel strategies for
meniscal injury should be developed.
microRNAs (miRNAs) are endogenous noncoding small
RNAs of approximately 22 nucleotides in length [17].
miRNAs are a new gene group that combines mRNA of
the target gene and controls gene expression by inhibition
of translation or degradation of mRNA [17,18]. The bio-
logical relevance of miRNAs has been investigated in
physiological and pathological conditions, revealing their
involvement in the fine tuning of biological events, such
as cell proliferation, differentiation and cell death [17,18].
miRNAs have been shown to play an important role in the
pathogenesis of human diseases [19-21]. Several thera-
peutic trials have examined the regulation of endogenous
miRNAs that are related to disease pathogenesis through
the in vivo administration of specific antisense oligoribo-
nucleotides or double-stranded (ds) miRNAs [22-24].
Several groups have reported recently that miR-210 is
a key player in angiogenesis in response hypoxia [25,26].
Overexpression of miR-210 has also been reported to
stimulate the formation of capillary-like structures in vitro
in normoxic conditions as well as vascular endothelial
growth factor (VEGF)-driven cell migration [25-27]. Such
angiogenesis is well known as one of the key factors for
tissue repair, and promoting angiogenesis during the initi-
ation phase of tissue repair could accelerate tissue healing
[10,28,29]. Shoji and colleagues demonstrated that intra-
articular injection of synthetic miR-210 could accelerate
anterior cruciate ligament healing in the rat model via
enhancement angiogenesis [30]. In their study, VEGF and
fibroblast growth factor (FGF)-2 were upregulated in the
injured ligament by administration of miR-210, which
also contributes to acceleration of ligament healing.
Therefore, we hypothesized that intra-articular injection
of synthetic miR-210 could enhance the injured meniscal
healing process. There have been no reports about intra-
articular injection of miRNA for the repair of meniscal
injury previously, so the purpose of the present study was
to investigate the effect of intra-articular injection ofsynthetic miR-210 on injured meniscal healing in a rat
model.
Materials and methods
All procedures were performed according to the Guide-
lines for Animal Experimentation, Hiroshima University,
and with the approval the Committee of Research Facil-
ities for Laboratory Animal Sciences, Graduate School of
Biomedical Sciences, Hiroshima University.
Animals
Twelve-week-old male Sprague–Dawley rats (Charles
River Laboratories Japan, Tokyo, Japan) that are skelet-
ally mature were used in these experiments [16,31,32].
The rats were housed at the Laboratory Animal Center
of Hiroshima University under standard diurnal condi-
tions of light/dark, were fed a standard commercial diet
and were given tap water ad libitum.
Preparation of double-stranded miR-210 and small
interfering RNA–atelocollagen complex
We used ds miR-210 that was designed for intra-articular
injection in the experimental group (sequences 66-CUG-
UGC-GUG-UGA-CAG-CGG-CUG-A-87 and 87-AGC-
CCC-UGC-CCA-CCG-CAC-ACU-G-66 labeled with
fluorescein amidite; B-Bridge International, Mountain
View, CA, USA). dsRNA molecules with no specific func-
tion were also prepared for use as a control group
(sequences 5-ATC-CGC-GCG-ATA-GTA-CGT-A-3 and
3-overhang dTdT/dTdT (sense/antisense) small interfer-
ing RNA negative control; B-Bridge International). Atelo-
collagen is a solution of highly purified collagen type 1
isolated from calf dermis by pepsin treatment (Koken,
Tokyo, Japan). The ds miR-210 and atelocollagen complex
was prepared by mixing an equal volume of atelocollagen
(in phosphate-buffered saline, pH 7.4) and dsRNA solu-
tion (20 μg/15 μl) and mixing by rotation at 4°C for 20 mi-
nutes. The control dsRNA and atelocollagen complex was
prepared identically. The miRNA/atelocollagen complexes
were prepared immediately before injection.
Surgical procedure
Fifty-six of the rats were anesthetized with an intraperi-
toneal injection of pentobarbital sodium (40 mg/kg).
The right knee was exposed using the medial parapatel-
lar approach with the patella laterally dislocated, and the
medial meniscus was identified at the knee joint in full
flexion. At the middle segment of each of the medial
meniscus, we made a full-thickness longitudinal tear
2 mm long in the avascular zone (white–white zone)
using a scalpel. The capsule and skin were then closed.
An intra-articular injection of dsRNA (total volume
30 μl) was administered through the patellar tendon into
the right knee joints using an insulin syringe with 29 G
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NJ, USA). The rats were allowed unrestricted weight-
bearing and motion of their knees.
Histologic and immunofluorescence analyses
At 4 weeks after injection, the medial meniscus was har-
vested and a frozen section was prepared. Frozen serial
sections of 6 μm thickness were derived from the hori-
zontal plane through the defect and prepared for histo-
logical analysis (n = 6 for each group). Hematoxylin and
eosin staining and safranin O staining were performed.
All specimens were given a histological score between 0
and 3 according to the following grading scale: 0 points,
no noticeable reaction at all; 1 point, no bridge linking
the two components; 2 points, connective tissue between
the two components; 3 points, explants, which had fi-
brous continuity between both sides of the gap [33]. All
specimens were evaluated by three of our colleagues
(YK, TN and TS) without knowledge of the treatment
received (blinded evaluation). At 12 weeks after intra-
articular injection, the knee joint was harvested and
fixed with 4.0% paraformaldehyde at 4°C for 24 hours.
The samples were then decalcified in 0.5 M ethylenedi-
aminetetraacetic acid (pH 7.5), and embedded in paraf-
fin. The sections were prepared at a thickness of 6 μm
and stained with safranin O staining (n = 6 for each
group). Three independent assessors (YK, TN and TS)
graded each section using a modified Mankin scale for
evaluation of cartilage degeneration [34].
For fluorescence microscopy of fluorescein amidite-
labeled miRNA-210 in meniscus samples, 6 μm serial
sections were mounted on saline-coated glass slides, air
dried and fixed with 4.0% paraformaldehyde at 4°C for
5 minutes. 4′,6-Diamidino-2-phenylindole solution was
then applied for 5 minutes for nuclear staining.
Isolation of meniscus and synovial cells
In vitro, the inner meniscus cells and synovial cells were
isolated in the rat knee joint from each donor (n = 6 for
each group). After the rat’s medial meniscus was har-
vested, the inner portion of the meniscus (cut from the
midpoint of the meniscus) was prepared. Inner meniscus
cells were isolated by collagenase treatment [35]. At-
tached cells were used as inner meniscus cells between
passages 2 and 4. Synovial cells were isolated by collage-
nase treatment and cultured. Synovial cells between pas-
sages 3 and 6 were used. ds miR-210 or ds negative
control RNA were transfected into the meniscus or syn-
ovial cells using Lipofectamine RNAiMax (Invitrogen,
Carlsbad, CA USA) according to the manufacturer’s
protocol. Cultures were maintained in Dulbecco’s modi-
fied Eagle’s medium (Wako, Osaka, Japan) containing
10% fetal bovine serum, 50 IU/ml penicillin and 50 μg/ml
streptomycin for 1 week.Transfection of double-stranded RNA in vitro
Isolated cells were maintained in Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum (Life Technolo-
gies, Grand Island, NY, USA) and 1% antibiotic–antimycotic
solution (Nacalai Tesque, Kyoto, Japan). Inner meniscus
cells (5 × 104) or synovial cells (5 × 104) were seeded into the
wells of 12-well plates and incubated for between 3 and
24 hours. The cells were transfected with miR-210 (20 nM)
or silencer negative control RNA (20 nM; Life Technologies)
using Lipofectamine RNAiMAX Transfection Reagent
(Life Technologies).
Real-time polymerase chain reaction
For PCR analysis, a 2 mm × 2 mm piece of meniscus in-
cluding the injured site was resected from the control
and miR-210 groups. In the normal group, the same size
piece of medial meniscus at the same site was harvested
from 12-week-old Sprague–Dawley rats (n = 5 for each
group). Total RNA was isolated from repaired tissue of
the meniscus in vivo and in vitro using TRIzol (Life
Technologies). Complementary DNA was synthesized
using Ready to Go You-Prime First-Strand Beads (GE
Healthcare, Chalfont, UK) with total RNA (1 μg) and
oligo(dT) primers. For miRNA expression analysis, re-
verse transcriptase reactions of mature miRNAs con-
tained a sample of total RNA, 50 nM stem-loop reverse
transcriptase primer, 10 × reverse transcriptase buffer,
100 mM each dNTPs, 50 U/μl MultiScribe reverse tran-
scriptase and 20 U/μl RNase inhibitor. The 15 μl reactions
were incubated in a thermocycler (BioRad, Hercules, CA,
USA). Real-time quantitative PCR was carried out using
TaqMan Gene Expression Assay probes for rno-miR-210,
snoRNA-135, VEGF, collagen type 1 alpha 1 (Col1a1),
FGF2 and ACTB. The expression levels for each gene
were assessed relative to the expression of snoRNA-135
for miR-210, and relative to ACTB for other genes. A
threshold cycle was observed in the exponential phase of
amplification, and quantification of relative expression
levels was performed using standard curves for the target
genes and the endogenous control. Geometric means were
used to calculate the delta-delta CT values and were
expressed as 2–ΔΔCT. The value of each control sample
was set at 1 and used to calculate the fold-change of target
genes.
Immunohistochemical analysis
For immunofluorescence staining, 6 μm serial sections
and meniscus and synovial cells fixed with 4.0% parafor-
maldehyde were prepared. After blocking by horse serum
(Vector Laboratories, Burlingame, CA, USA), specimens
were immediately stained with rabbit polyclonal anti-VEGF
or anti-basic FGF antibody (concentration 1:100; Abcam,
Cambridge, MA, USA), Ki67 antibody (concentration
1:100; Novus, Littleton, Colorado, USA), goat polyclonal
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Cruz Biotechnology, Santa Cruz, CA, USA), mouse poly-
clonal anti-collagen type 2 antibody (concentration 1:100;
Abcam) or fluorescein-labeled GSL I-isolectin B4 (concen-
tration 1:100; Vector Laboratories). The secondary anti-
bodies used were Alexa Fluor 488-conjugated or Alexa
Fluor 568-conjugated goat anti-rabbit IgG for VEGF-A,
Ki67 and FGF2, Alexa Fluor 488-conjugated or Alexa
Fluor 568-conjugated rabbit anti-goat IgG for collagen
type 1, and Alexa Fluor 488-conjugated or Alexa Fluor
568-conjugated goat anti-mouse IgG for collagen type 2
(concentration 1:500; all from Molecular Probes/Invitro-
gen, Carlsbad, CA, USA). 4′,6-diamidino-2-phenylindole
solution was applied for 5 minutes to detect nuclear
staining.Figure 1 Histological findings of the meniscus at 4 weeks. (A) Hemato
miR-210 group was filled with repaired tissue stained with safranin O, while
lower panels, worst result (bar = 100 μm). (C) Histological score of the miR-
control group (1.0 ± 1.0 point) (*P < 0.05, n = 6 for each group). (D) Detectio
distribution of green fluorescence was observed in the meniscus around th
atelocollagen complex into the joint (bar = 100 μm). Expression of green flu
(bar = 25 μm). Arrows, FAM-labeled ds miR-210/atelocollagen complex. DAFor each section, the number of Ki67-positive cells
and the number of all cells were counted at × 40 magni-
fication, and the ratio of Ki67-positive cells to all cells
was calculated (n = 5 for each group). The number of
blood vessels that were identified as positive isolectin
B4, the marker for rat endothelial cells, was counted at ×
40 magnification (n = 5 for each group). Five sections
were randomly evaluated in each rat for counting cells
and blood vessels.
Statistical analysis
All data were expressed as the mean ± standard devi-
ation. For the statistical analysis, one-way analysis of
variance followed by Tukey’s post hoc analysis was used
for the detection of differences between three groups,xylin and eosin staining. (B) Safranin O staining: the injured site of the
that of the control group was not repaired. Upper panels, best result;
210 group (2.3 ± 0.8 points) was significantly higher than that of the
n of fluorescein amidite (FAM)-labeled double-stranded (ds) miR-210:
e injured site 24 hours after injection of the FAM-labeled ds miR-210/
orescence was observed in the cytoplasm of cells in high-power views
PI, 4′,6-diamidino-2-phenylindole.
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tion of differences between two groups. P < 0.05 was
considered statistically significant.
Results
Intra-articular injection of miR-210 can accelerate
meniscal healing
The injured site of the miR-210 group was filled with
repaired tissue stained with safranin O, while that of the
control group was not repaired. In the miR-210 group,Figure 2 Histological findings of the knee joint at 12 weeks. (A) Hema
the miR-210 group was morphologically healed whereas the tear in the me
staining revealed that the degeneration of articular cartilage in the miR-210
Upper panels, best result; lower panels, worst result. (B) Meniscal healing sc
than in the control group (1.3 ± 0.6 points) (*P < 0.05, n = 6 for each group)
advanced than in the miR-210 group. (C) Mankin score in the miR-210 gro
(5.6 ± 1.4 points), showing a significant difference between the two groups
prevented articular cartilage degeneration.one-half of the rats showed complete meniscal healing,
and the remaining rats showed high or intermediate
healing. In the control group, no rat showed complete
meniscal healing, and one-half of the rats showed no
meniscal healing. The histological score of the miR-210
group (2.3 ± 0.8 points) was significantly higher than that
of the control group (1.0 ± 1.0 points) (P < 0.05, n = 6 for
each group) (Figure 1A,B,C). Fluorescein amidite-labeled
ds miR-210/atelocollagen complex was taken in cells of
the whole meniscus after intra-articular injection, andtoxylin and eosin staining and safranin O staining: the injured site in
niscus still remained in the control group (bar = 100 μm). Safranin O
group was lower than that of the control group. Arrow, injured site.
ore in the miR-210 group (3.0 ± 0.0 points) was significantly higher
. Degenerative change of cartilage in the control group was more
up (1.0 ± 0.4 points) was significantly lower than in the control group
(*P < 0.05, n = 6 for each group). Intra-articular injection of miR-210
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ticular (Figure 1D).
Intra-articular injection of miR-210 prevents articular
cartilage degeneration
Macroscopic findings showed that the injured site in the
miR-210 group was morphologically healed, whereas the
tear in the meniscus still remained in the control group
at 12 weeks after the intra-articular injection. There was
no obvious synovitis in both groups. In the control
group, OA changes such as fibrillation, irregularity, ero-
sion and loss of cartilage surface were observed. Histo-
logical findings for six out of six rats in the miR-210
group but only for two out of six rats in the control
group showed complete meniscal healing. The meniscal
healing score of the miR-210 group was significantly
higher than that of the control group (P < 0.05, n = 6 for
each group) (Figure 2A). Safranin O staining revealedFigure 3 Gene expression analysis by real-time PCR in the meniscus a
miR-210, collagen type 1 alpha 1 (Col1a1), collagen type 2 alpha 1 (Col2a1)
factor-2 (FGF2) was examined using real-time PCR. Expression of miR-210, C
than that in the control and normal groups (*P < 0.05). There was no signif
the control and normal groups (*P < 0.05, N.S. (no significant difference), nmore severe degenerative change of the cartilage in the
control group compared with the miR-210 group. In the
control group, OA changes such as fissure of cartilage
surface, loss of outer layer cartilage cells and reduction
of stainability were observed (Figure 2B). Regarding the
Mankin score, there was a significant difference be-
tween the two groups (P < 0.05, n = 6 for each group)
(Figure 2C).
Gene expression analysis of the meniscus
For gene expression analysis in the meniscus, mature
miR-210, Col1a1, collagen type 2 alpha 1 (Col2a1), VEGF
and FGF2 expression was examined using real-time PCR.
The expression of miR-210, Col2a1, VEGF and FGF2 in
the miR-210 group was significantly higher than that in
the control and normal groups (P < 0.05, n = 5 for each
group) (Figure 3). There is no significant difference in ex-
pression between the control and normal groups. Fort 4 weeks following intraarticular injection. Expression of mature
, vascular endothelial growth factor (VEGF) and fibroblast growth
ol2a1, VEGF and FGF2 in the miR-210 group was significantly higher
icant difference in miR-210, Col2a1, VEGF and FGF2 expression between
= 5 for each group).
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tween each group.
In immunohistochemistry, VEGF and FGF2 intensely
expressed on the surface of the meniscus, around the in-
jured site and in the red zone in the miR-210 group
compared with the control group (Figure 4A). Type 2
collagen expression was observed around the injured site
of the meniscus in the miR-210 group, while its expres-
sion was sparse in the control (Figure 4B). In the miR-
210 group, newly formed vessels were observed around
the injured site, while few blood vessels were observed
in the control group. The number of blood vessels in the
miR-210 group was significantly higher than that in the
control group (P < 0.05, n = 5 for each group) (Figure 4C).Figure 4 Immunohistochemistry of meniscus at 4 weeks after intra-ar
growth factor (VEGF; upper) and fibroblast growth factor-2 (FGF2; lower). VEGF
injured site and in the red zone in the miR-210 group compared with the con
type 2 collagen. Type 2 collagen expression was observed around the injured
group. Arrow, injured site. Bar = 100 μm. (C) Isolectin B4 staining and the num
injured site in the miR-210 group, while little blood vessels were observed in
Bar = 100 μm. Number of blood vessels in the miR-210 group was significantl
(D) Immunohistochemistry of Ki67 and the ration of proliferative cells. In the m
site. Arrow, injured site. Proliferative cells in the miR-210 group were significan
difference), n = 5 for each group).In the miR-210 group, many proliferative cells that had
an immunoreactivity of Ki67 were observed around the
injured site. Proliferative cells in the miR-210 group
were significantly higher than those in the control group
(P < 0.05, n = 5 for each group) (Figure 4D).
miR-210 upregulated Col2a1 expression in the inner
meniscus cells and VEGF and FGF2 expression in the
synovial cells
Real-time PCR revealed that Col2a1 expression was sig-
nificantly upregulated in the inner meniscus cells, and
immunocytochemistry also demonstrated that miR-210
could enhance the expression of collagen type 2 in the
meniscus cells (P < 0.05, n = 6 for each group) (Figure 5A,B).ticular injection. (A) Immunohistochemistry of vascular endothelial
and FGF2 expressed intensely on the surface of the meniscus, around the
trol group. Arrow, injured site. Bar = 100 μm. (B) Immunohistochemistry of
site of the meniscus in the miR-210 group compared with the control
ber of blood vessels. Newly formed vessels were observed around the
the control. White arrow, injured site; yellow arrow, blood vessels.
y higher than that in the control group (*P < 0.05, n = 5 for each group).
iR-210 group, many proliferative cells were observed around the injured
tly higher than that in the control group (*P < 0.05, N.S. (no significant
Figure 5 Gene expression analyses in inner meniscus cells after overexpression of miR-210. (A) Real-time PCR analysis of collagen type 1
alpha 1 (Col1a1), collagen type 2 alpha 1 (Col2a1), vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF2) at 7 days after
in vitro transfection of inner meniscus cells. Expression of only Col2a1 was significantly higher than that in the control group (*P < 0.05, N.S. (no
significant difference), n = 6 for each group). (B) Immunohistochemical analysis indicates that collagen type 2 was highly expressed in the miR-210
group (bar = 100 μm). These results demonstrate that miR-210 could enhance the expression of collagen type 2 in the meniscus cells. ds, double
stranded.
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significantly upregulated in the synovial cells (P < 0.05,
n = 6 for each group) (Figure 6A). Immunocytochem-
istry indicated that VEGF and FGF2 expression were
enhanced in the synovial cells (Figure 6B).
Discussion
Generally, partial or overall meniscectomy is performed
to treat injured meniscus, especially in the avascular re-
gion. However, this results in reduced articular stability
and exposes the articular cartilage surface to higher con-
tact stress. The meniscus is dimorphic tissue, and it is
very likely that an injury located in the outer one-third
of the meniscus (red zone) is repaired more effectively
than an injury in another area, thanks to the red zone’s
dense blood vessels. Avascularity of the inner two-thirds
of the meniscus (white zone) is associated with limited
healing potential of this zone. The ideal treatment for
meniscal injury is considered to promote both angiogen-
esis from the perimeniscal capillary plexus and upregula-
tion of extracellular matrix in both inner and outer
meniscus regions.Recently, miRNAs have attracted immense attention
because of their pivotal role in human disease, and they
have been proposed as potential new therapeutic targets.
Several therapeutic trials to regulate miRNA in vivo have
been undertaken [24,30]. It has been reported that miR-
210 is a crucial molecule of the endothelial cell response
to hypoxia and that the targets of miR-210 are ephrin-
A3, E2F3, MN, ACVR1B, NPTX1, RAD52, CASP8AP2,
FGFRL1 and HOXA-1/9, which have important func-
tions in cell survival, migration and differentiation
[25,36-43]. Several papers have reported the involvement
of miR-210 in angiogenesis. Hu and colleagues demon-
strated that local injection of ds miR-210 generated in a
minicircle vector into the myocardium can improve
angiogenesis, inhibit apoptosis and improve cardiac func-
tion in mice [44]. Shoji and colleagues demonstrated that
intra-articular injection of ds miR-210 can promote the
healing of partially torn anterior cruciate ligaments
through enhancement of angiogenesis [30]. In their re-
search, collagen type 1 expression was upregulated in the
injured ligament after the administration of miR-210, al-
though it was unclear whether collagen type 1 production
Figure 6 Gene expression analyses in synovial cells after overexpression of miR-210. (A) Real-time PCR analysis of collagen type 1 alpha 1
(Col1a1), collagen type 2 alpha 1 (Col2a1), vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF2) at 7 days after in vitro
transfection of synovial cells. Expression of Col2a1 was not detected in both groups. Expression of VEGF and FGF2 was significantly higher than in
the control group (*P < 0.05, N.S. (no significant difference), n = 6 for each group). (B) Immunohistochemical analysis indicates that VEGF and FGF2
were highly expressed in the miR-210 group (bar = 100 μm). These results demonstrated that miR-210 could enhance the expression of VEGF and
FGF2 expression in synovial cells. ds, double stranded.
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current study, the production of collagen type 2 was en-
hanced by the administration of miR-210 in vivo, and not-
ably this phenomenon could be observed in isolated
cultured meniscus cells. This indicated the direct effect of
miR-210 on upregulation of collagen type 2 in inner me-
niscus cells. The main composition of the extracellular
matrix of the meniscus is collagen type 1, but in the inner
region of the meniscus, which is composed of avascular
tissue, extracellular matrix contains collagen type 2 and a
greater number of chondrocytic morphology cells than in
the outer region of the meniscus [45,46]. Several studies
have attempted upregulation of collagen type 2 in menis-
cus cells using cytokines, mechanical stress and cells
[10,14,47,48].
The effect of growth factors on stimulating angiogen-
esis from perimeniscal capillaries to enhance meniscal
healing has been the focus of several studies [4,9,49,50].
VEGF and FGF2 are well known as potent angiogene-
tic factors. FGF2 is recognized to stimulate fibroblastproliferation, angiogenesis and enhancement of collagen
synthesis [51]. Narita and colleagues demonstrated that
FGF2 can stimulate the proliferation of meniscus cells in
an organ culture model [52]. VEGF is able to induce
endothelial cell migration, and several studies demon-
strated attempts to promote meniscal healing by VEGF,
but they did not achieve sufficient vessel formation and
meniscal healing [9,49]. Administration of single growth
factor is not always successful for tissue regeneration.
Synovium plays an important role in meniscal healing,
and it is reported to produce several growth factors to
enhance meniscal healing [10,53,54]. In our results, high
expression of VEGF and FGF2 was observed in vivo after
intra-articular injection of miR-210. To examine which
cell type in the meniscal lesion contributed to the menis-
cal healing by the miR-210 injection, overexpression of
miR-210 was conducted in isolated inner meniscus cells
or synovial cells in rats in vitro. VEGF and FGF2 expres-
sion in synovial cells were upregulated by overexpression
of miR-210. Immunohistochemistry of meniscus at 4 weeks
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not only on the injured site but also on the surface of the
meniscus, which might mean induction of synovium to
the injured site along the surface of the meniscus.
miR-210 is recognized to have the potent function of
angiogenesis, and in this study intra-articular injection of
ds miR-210 could enhance the angiogenesis around the in-
jured site of the meniscus. As for the cell proliferation,
miR-210 could promote cell proliferation in the meniscus.
Moreover, miR-210 could directly promote collagen syn-
thesis in inner region meniscus cells. It has been reported
that factors affecting tissue healing in the joint and a heal-
ing response include the biomechanical forces, the sur-
rounding tissues, blood supply, nutrient delivery, synovial
fluid and the supply of growth factors [10,28]. miR-210 de-
livery into the knee joint may therefore have several pleio-
tropic effects on several tissues including the meniscus
itself, the synovium and surrounding tissues, in addition
to the proangiogenic roles that were investigated here.
Hundreds of miRNA target genes are predicted by com-
puter analysis, which means that miRNA therapy has
more multifactorial effects on tissue regeneration com-
pared with single growth factor administration. Further-
more, unlike cell therapy, miRNA therapy does not
require cells to be harvested and cultured.
The limitations of this study are as follows. First, we
could not analyze the local or systemic adverse effects of
an intra-articular injection. miR-210 plays a role in the
induction of VEGF expression, which is recognized as
harmful for articular cartilage. We have confirmed that
intra-articular injection of ds miRNA is not able to be
taken up by chondrocytes in normal cartilage (data not
shown). However, there is the possibility that ds miRNA
can be taken up by OA cartilage, which might promote
cartilage degeneration. Nagata and colleagues demon-
strated the systemic distribution of ds miRNA after
intra-articular injection [55]. They showed that injected
ds miR-15a, which induces cell apoptosis, was detected
in the liver, but no apoptosis in the liver was observed.
Second, the molecular mechanism is still unclear. Sev-
eral reports link miR-210 to the pathogenesis of cancer,
so further investigation including the validation of target
genes is required.
Conclusion
The present study demonstrates that intra-articular in-
jection of ds miR-210 can promote the healing of
damaged white zone meniscus through the promotion of
collagen type 2 production in meniscus cells and
through the enhancement of VEGF and FGF2 expression
in synovial cells with angiogenesis and cell proliferation.
Administration of miRNA would be expected to bring
about more effects via regulation of many gene net-
works, which would be an advantage of miRNA therapy.The results of this study suggest that administration of
synthetic miR-210 would be a meniscus treatment op-
tion, although the exact process and molecular mechan-
ism of meniscal healing have not been fully elucidated.
Intra-articular injection of ds miRNA in vivo is a poten-
tial new and exciting strategy for the future treatment of
injured joints. However, to determine its competency as
a therapeutic agent, more extensive study involving elu-
cidation of the target genes and of the adjustment
process is necessary.
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